Wegovy received FDA approval in 2021 for weight loss in adults and teens with obesity or overweight, and in 2024 gained additional approval to help reduce cardiovascular risk in adults with obesity or overweight and heart disease
A discussion on patient perspectives about weight change is based on key preclinical and clinical trials, meta-analyses, and reviews and is supplemented by the authors clinical judgment and research experience in the field
For researchers, we plan to make presentations at the American Diabetes Association (ADA) and Diabetes Canada annual meetings as well as publish scientific papers
Ulbricht C, Basch E, Szapary P, et al
The risk of drug interactions increases when patients obtain products from unreputable sources
Thats where microdosing GLP-1 comes in